Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Bionano Genomics, Inc. Common Stock

BNGO

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.946 – $1.03
Volume 58,788
Market cap $13M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$13.15M
Price / earnings
—
Price / book
0.47×
Price / sales
0.42×
EV / sales
0.4×
EV / EBITDA
-0.59×

Profitability

Earnings per share
-$2.15
Return on assets
-65.05%
Return on equity
-106.74%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.13×
Current ratio
2.07×
Quick ratio
1.54×
Cash ratio
0.35×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.09M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BNGO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$8.28M$8.17M$6.69M$7.95M$7.37M$6.73M$6.46M$8.16M
Cost of revenue$4.33M$3.86M$3.44M$4.55M$4M$3.26M$3.52M$4.75M
Gross profit$3.95M$4.31M$3.25M$3.4M$3.37M$3.48M$2.94M$3.42M
Selling, general and administrative$7.44M$8.54M$8.01M$8.71M$9.06M$8.35M$9.03M$11.75M
Research and development$3.04M$2.99M$3.14M$3.23M$2.84M$2.93M$2.37M$3.47M
Total operating expenses$10.49M$11.53M$11.15M$11.94M$11.91M$11.28M$11.4M$15.36M
Operating income-$6.54M-$7.22M-$7.9M-$8.54M-$8.54M-$7.8M-$8.47M-$11.94M
Interest expense$63K$76K$223K$0$268K$204K$290K$0
Income before taxes-$6.45M-$7.42M-$8.29M-$7.9M-$8.49M-$6.85M-$3.1M-$20.12M
Income taxes$8K$7K$10K$35K$14K$10K$7K$1K
Net income-$6.45M-$7.42M-$8.3M-$7.93M-$8.5M-$6.86M-$3.1M-$20.13M
Net income attributable to common shareholders-$6.45M-$7.42M-$8.3M-$7.93M-$8.5M-$6.86M-$3.1M-$20.13M
EBITDA-$4.25M-$4.92M-$5.59M-$6.2M-$6.16M-$5.42M-$6.03M-$9.41M
Basic earnings per share-$0.54-$0.64-$0.76-$0.77-$1.59-$1.99-$1.15-$12.21
Diluted earnings per share-$0.54-$0.64-$0.76-$0.77-$1.59-$1.99-$1.15-$12.21

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Sarepta Therapeutics (SRPT) Q3 Earnings Lag Estimates

Sarepta Therapeutics (SRPT) reported quarterly earnings of $0.13 per share, missing consensus estimates of $0.37 per share, representing a -64.87% earnings surprise. While revenues of $381.35 million exceeded expectations by 9.43%, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions. The stock has underperformed the S&P 500 by 24.1% year-to-date.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 27, 20251-for-60reverse split
Aug 7, 20231-for-10reverse split